FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients; Triplet Therapeutics quietly shuts down

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: FDA and large compound pharmacies settle a long-running dispute over a key list for ingredients By Ed Silverman Adobe At issue has been the approach taken by the FDA to approve the use of active ingredients, which could be used to make compounded medicines. Read More STAT+: Merck pays $250 million to license a Moderna skin-cancer vaccine candidate By Adam Feuerstein Alex Hogan/STAT Results from this study will be announced by year's end, but the timing of the deal suggests Merck and Moderna have seen encouraging data. Read More Sponsor content by Sanofi Making strides to help protect our most vulnerable this flu season New guidance from the CDC's Advisory Committee on Immunization Practices granted a preferential recommendation for specific flu vaccines for adults 65 years and older. Learn more about the importance of following the science when making informed healthcare decisions for older adults. FDA authorizes updated Covid-19 boosters for kids as young as 5 By Andrew Joseph JEFF KOWALSKY/AFP via Getty Images Previously, the newer versions of the Covid booster shots were only available to adults and kids as young as 12. Read More STAT+: Triplet Therapeutics, biotech company focused on Huntington's, quietly shuts down By Allison DeAngelis Adobe The company, based in Cambridge, Mass., was developing drugs for repeat expansion disorders such as Huntington's disease. Read More Wednesday, October 12, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser